Former NASA astronaut, official joins Venus Aerospace board

astronaut appointment

Pamela Melroy, a member of the United States Astronaut Hall of Fame, has joined Venus Aerospace's board of directors. Photo courtesy Venus Aerospace/PRNewsFotos.

Retired Air Force colonel and former NASA astronaut Pamela Melroy, who previously served as deputy administrator of NASA, recently joined the board of directors at Houston-based Venus Aerospace.

Venus Aerospace, a startup founded in 2020, develops rocket engine technology, including rotating rocket detonation engines for hypersonic flights. These engines promise higher power, greater fuel efficiency and lower emissions than conventional rocket engines or jet engines, according to the Interesting Engineering website. The global rocket propulsion market is expected to grow from $9.5 billion in 2025 to $29.9 billion by 2034, according to a forecast by ResearchAndMarkets.com.

“Advanced rocket propulsion has been of interest to me for over a decade, and Venus Aerospace’s recent achievements in demonstrating the stability of rotating detonation rocket engines represent a significant development,” says Melroy, who left NASA earlier this year and is now a self-employed consultant living in Arlington, Virginia.

Melroy, a member of the United States Astronaut Hall of Fame, has built an illustrious career in the aerospace sector. Aside from being a NASA official, she was:

  • One of only two female astronauts to command a space shuttle mission
  • Deputy program manager of Orion space exploration initiatives at aerospace and defense contractor Lockheed Martin
  • Senior technical adviser and director of field operations for the Federal Aviation Administration’s Office of Commercial Space Transportation, where she came up with the first safety guidelines for commercial human spaceflight
  • Deputy director of the Tactical Technology Office at the Defense Advanced Research Projects Agency (DARPA).
  • An adviser for the establishment of the Australian Space Agency

Venus Aerospace said in a news release that as a leader at three federal agencies, “Melroy shaped America’s strategy in space, accelerated commercial space partnerships, and deepened space exploration.”

Sassie Duggleby, co-founder and CEO of Venus Aerospace, called Melroy “a preeminent leader in the world of aerospace.”

In May, Venus Aerospace completed the inaugural test flight of its rotating detonation rocket engine. The startup, whose headquarters is at the Houston Spaceport, says it’s the only company in the world that has manufactured a flight-proven, high-thrust rotating detonation rocket engine.

On the horizon for Venus Aerospace is production of Stargazer M4, a high-speed aircraft capable of two-hour global travel.

Venus Aerospace’s investors include Airbus Ventures, America’s Frontier Fund, Trousdale Ventures, and Prime Movers Lab. The startup also gets support from the Air Force Research Laboratory (AFWERX), the Air Force, NASA and DARPA.

Jordan Blashek, co-founder and managing partner of America’s Frontier Fund, which backs startups creating breakthrough technologies, said his firm’s investment in Venus Aerospace “underscores our focus on supporting American companies that are revolutionizing industries of the future.”

“With recent hypersonic advancements from China and Russia, safeguarding American innovation and securing our industrial base has never been more urgent,” Blashek added. “Venus Aerospace is poised to redefine hypersonic flight and ensure America’s continued leadership in aerospace innovation.”

Since its founding, Venus Aerospace has raised $78.3 million in investments, according to PitchBook data.

From Your Site Articles
This Houston company is one step closer to enabling high-speed global travel. Photo courtesy of Venus Aerospace

Houston startup with hypersonic engine tech adds new investor

it's rocket science

A Houston-based company that's developing an engine that'll enable one-hour global transportation has announced its latest investor.

Venus Aerospace released the news that Silicon Valley venture capital firm, Airbus Ventures, has joined its team of investors. The supersonic combustion engine technology — more akin to a rocket's engine than an airplane's — is revolutionary because allows for travel at a higher elevation. Jet engines rely on air outside of the aircraft to combust, and rocket engines work with a system that supplies air internally.

“Venus has developed the world’s first liquid-propellant rotating detonation rocket engine (RDRE) with a double-digit percentage increase in efficiency over standard regular engines, making the hypersonic economy possible,” says Sassie Duggleby, CEO and co-founder of Venus, in a news release. “We’re delighted to bring Airbus Ventures into the Venus family and look forward to growing our collaboration as we harness the future of hypersonic flight.”

Duggleby founded Venus Aerospace with her husband and CTO Andrew in 2020, before relocating to the Houston Spaceport in 2021. Last year, Venus raised a $20 million series A round. That round, led by Prime Movers Lab, is being used to fund tech development and initial flight testing for building its Mach 9 hypersonic drone and Mach 9 spacecraft. Venus did not disclose how much their newest investor has contributed.

“In the world of RDREs, their pioneering approach — designing, building, and demonstrating the first liquid, storable-propellant fueled rotating detonation rocket engine — unlocks advanced aircraft capabilities and opens new vistas on our whole planetary system,” says Airbus Ventures Managing Partner Thomas d’Halluin in the release. “Venus’ compact, low mass, high efficiency engine capability will have an immediate impact on lunar and martian landers, space mobility and logistics, and deep space mission proposals.

"Here on Earth today, we will see unprecedented performance gains for drones of all kinds, and more practical and faster-than-anticipated opportunities for ultra-high-speed passenger and cargo rocket plane flights,” he continues.

Venus, which as has contracts with NASA and US Defense Agencies, has plans to test its technology this summer at its headquarters in the Houston Spaceport.

“With the strong support of Airbus Ventures now joining our investor syndicate, our next round will let Venus take the final step from lab to prototype as we fly our drone to Mach 3 under RDRE power," says Andrew Duggleby, in the release. “This will include long-duration engine runs this summer at Spaceport Houston, as well as the design, build, and flight of our drone with the broader Venus team and our incredible partners.”

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

New 'living pharmacy' biotech company launches out of Rice venture studio

fighting cancer

Rice University’s biotech venture studio RBL LLC has launched a new “living pharmacy” company, Duracyte, designed to make cancer treatment easier on patients.

Backed by an up to $45 million Advanced Research Projects Agency for Health (ARPA-H) award, Duracyte aims to commercialize implantable biohybrid pharmacy devices that are designed to produce therapeutic proteins inside the human body around the clock, replacing the need for regular injections and infusions for some cancer patients.

The company’s main platform is its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR), a rechargeable, implantable device that can sense biological signals, monitor tumor environments and adjust therapeutic output in real time. HAMMR has wireless communication capabilities, which allow patients and clinicians to remotely monitor results through an app every five minutes and make changes to treatment plans without a hosptial visit. Additionally, the device can generate its own oxygen supply, which is key for the therapeutic cells’ survival.

“Biologic medicines such as monoclonal antibodies, cytokines and metabolic regulators already account for a significant share of modern therapeutics, but the way we deliver them today often requires frequent injections or infusions that can be demanding for patients and lead to inconsistent drug levels,” Daniel Anderson, MIT professor and co-founder of Duracyte, said in a news release. “Our vision is to enable a continuous, stable therapy by producing these medicines directly inside the body, which could improve treatment consistency, reduce side effects and ultimately transform how biologic therapies are delivered across many diseases.”

Duracyte’s first clinical trial is slated to begin by the end of 2026 and will focus on recurrent ovarian cancer. The Phase I study will build upon existing work on encapsulated cytokine pharmacy technology, and the company hopes that within a few years this treatment can reach clinical application.

The development of Duracyte is supported by ARPA-H's Targeted Hybrid Oncotherapeutic Regulation (THOR) project, which supports a multidisciplinary research consortium co-led by Omid Veiseh, a professor of bioengineering at Rice. The consortium also includes others at Rice, The University of Texas MD Anderson Cancer Center, Stanford University, Carnegie Mellon University, Northwestern University and the University of Houston, plus industry collaborators like Chicago-based CellTrans.

“What we are building is the culmination of years of progress in cell engineering, biomaterials and implantable device technology,” Veiseh added in the release. “By combining these advances with real-time sensing and adaptive drug delivery, we are working with the support of RBL to create a true ‘living pharmacy’ that can deliver continuous, precisely controlled biologic therapies and fundamentally change how these treatments reach patients.”

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. Duracyte is the third company launched by RBL, including Sentinel BioTherapeutics, a clinical-stage immunotherapy company developing localized cytokine therapies for solid tumors, and SteerBio, a regenerative medicine company targeting lymphedema.

“Duracyte exemplifies the kind of breakthrough that Houston’s ecosystem is built to produce,” Paul Wotton, managing partner of RBL LLC and co-founder of Duracyte, added in the release. “With world-class clinical infrastructure, exceptional engineering talent and initiatives like the Texas Biotech Task Force driving alignment across industry, investment and talent, this region is uniquely positioned to move the most ambitious ideas in medicine from concept to patient, faster than anywhere else.”

Houston energy hub opens new fundraising cohort to fuel startups

Apply Now

EnergyTech Cypher has opened applications for its second Liftoff fundraising program.

Applications close May 20 for the 10-week virtual fundraising sprint. The program is geared toward energy and climatech founders preparing to raise their first institutional round. It will cover fundraising requisites, like pitch materials, term sheet negotiation and round closing, according to a release from EnergyTech Cypher.

The program kicks off June 1 and runs every Monday from 1-3 p.m. CST. It will conclude with an in-person capstone simulation in Houston on August 3, where founders will work to close a mock round.

Jason Ethier, EnergyTech Cypher founder and CEO, will lead the program with Payal Patel, an EnergyTech fellow and entrepreneur in residence.

The program is available through Cephyron, EnergyTech Cypher's new investor relationship management platform, built specifically for energy and climatech founders. Users must have a Cephyron Boost membership to participate in the Liftoff program.

The Cephyron IRM app recently went live and is available to founders at any point in their fundraising process, according to the news release. The platform aggregates investor data, tracks market signals and delivers curated weekly recommendations.

EnergyTech Cypher launched Liftoff last year. The inaugural cohort included 19 startups, including Houston-based AtmoSpark Technologies, The Woodlands-based Resollant and others. Each participant closed at least one fundraising deal, according to EnergyTech Cypher.

EnergyTech Cypher rebranded from EnergyTech Nexus earlier this year. It also launched its CoPilot accelerator in 2025. The inaugural group presented its first showcase during CERAWeek last month.

EnergyTech Cypher's annual Pilotathon Pilot Pitch and Showcase applications also opened this month. Find more information here.

---

This article originally appeared on EnergyCaptialHTX.com.

Cancer diagnostics startup wins top prize at annual Rice competition​

winner, winners

Rice University student-founded companies took home a total of $115,000 in equity-free funding at the annual Liu Idea Lab for Innovation and Entrepreneurship's H. Albert Napier Rice Launch Challenge last week.

2025 Rice Innovation Fellow Alexandria Carter won the top prize and $50,000 for her startup Bionostic. The startup offers personalized diagnostics for cancer patients by using 3D culturing through its Advanced Tumor Landscape Analysis System (ATLAS) platform.

Carter is working toward her PhD in bioengineering in Professor Michael King's laboratory. She recently completed the Rice Innovation Fellows program and plans to commercialize ATLAS, according to a news release from Rice.

Actile Technologies, founded by another former Rice Innovation Fellow, Barclay Jumet, won second place and $25,000. The company is developing and commercializing textile-integrated technologies. InnovationMap first covered Jumet's wearable technology back in 2023.

Kairos took home the third-place prize and $15,000, plus the $2,000 audience choice award and the $5,000 undergraduate business award. Founded last year by Sanjana Kavula and Adhira Tippur, Kairos is an AI-powered patient intake platform built specifically for independent dental practices.

The NRLC features top startups founded by undergraduate, graduate and MBA students at Rice each year. The top three finishers were named among a group of five finalists earlier this year, which also included HAAST Autonomous and Project Kestrel.

HAAST is developing an unmanned aircraft for organ transport, while Kestrel uses machine learning to organize bird photographers’ photo collections.

Teams presented multiple five-minute pitches throughout the application process over Zoom and in-person before the five finalists presented at the NRLC Championships April 21 at the Rice Memorial Center. Each finalist walked away with an equity-free investment.


Other awards went to:

UnitCode

  • $5,000 MBA Venture Award

HAAST Autonomous

  • $2,500 Chan-Kang Family Prize for Bold Ambition
  • $1,000 Healthcare Innovations Prize

Telstar Networks

  • $2,500 Outstanding Undergraduate Startup Award

Multiplay

  • $1,500 Frank Liu Jr. Prize for Creative Innovation in Music, Fashion, & the Arts

Butterfly Books

  • $1,500 Social Impact Award

SOOZ

  • $1,000 Interdisciplinary Innovation Prize sponsored by OURI

Dooly

  • $1,000 Consumer Goods Prize

Project Kestrel

  • $1,000 AI Prize

Veloci Running won the NRLC last year for its naturally shaped running shoe. Founder and CEO Tyler Strothman recently told InnovationMap that the company has gone on to sell roughly 10,000 pairs of its flagship Ascent shoe, designed to relieve lower leg tightness and absorb impact. Read more here.

View All Listings